Brought to you by 
~Novo Industri has acquired an additional 78% of ZymoGenetics
13 Jul 1999
Executive Summary
Novo Industri has acquired an additional 78% of ZymoGenetics (researching growth factors and blood coagulation products) bringing its stake in ZymoGenetics to 94%. Novo plans to acquire the remaining 6% in the near future.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
~Novo Industri has acquired an additional 78% of ZymoGenetics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice